Skip to main content

Karo Bio Selects Elsevier's Reaxys to Support Medicinal Chemistry Projects

Premium

Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Specifically, Karo's chemists are using Elsevier's Reaxys and Reaxys Medicinal Chemistry solutions. These tools give researchers access to biological and chemistry data from periodicals, peer-reviewed journal articles, and patents.

The financial details of the agreement were not disclosed.

Elsevier's Reaxys portfolio is one of several products for drug discovery and development offered by the company's life science solutions business. Other tools in the unit include ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA, and Embase.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.